Healthcare Capital Corp. (HCCC) Adjourns Vote for Alpha Tau Deal Again
Healthcare Capital Corp. (NASDAQ:HCCC) announced that it has once again adjourned its special meeting with cancer drug developer Alpha Tau until later today.
The meeting, which was supposed to be held earlier this morning, was convened and then adjourned until 4:00p.m. Eastern Time, this afternon. HCCC, which adjourned the original meeting on Tuesday, February 15, stated that it still needs additional time to satisfy certain closing conditions. The SPAC noted on Tuesday that although a sufficient number of stockholders had voted to approve the proposed business combination, not all of the conditions to effect the closing were satisfied.
HCCC is financing the deal with $275 million from its current trust supplemented by a $92 million PIPE at $10 per share. The PIPE drew participation from Yozma, Grand Decade Development, OurCrowd, Medison Group, Regah Ventures and Apax Partners Co-Founders Alan Patricof and Sir Ronald Cohen.
HCCC opened today at $10.20, and spiked to a high of $11.45, but has since dropped to $9.90.
Healthcare Capital originally announced its $650 million deal with Alpha Tau last summer on July 8. Jerusalem-based Alpha Tau is developing unique cancer treatments that utilize alpha radiation to attack tumors with reduced damage to surrounding tissues and cells.
ADVISORS
- Citigroup is acting as financial advisor to Alpha Tau.
- Citigroup, Piper Sandler, and Cantor Fitzgerald are acting as joint placement agents on the PIPE.
- Cantor Fitzgerald is acting as a capital markets advisor to HCC.
- Value Base M&A Ltd. is also acting as financial advisor on the transaction.
- Latham & Watkins LLP and Meitar | Law Offices are acting as legal advisors to Alpha Tau.
- Ellenoff Grossman & Schole LLP and FBC & Co. are acting as legal advisors to HCC.
- Winston & Strawn LLP is acting as legal advisor to the placement agents.